Clinical Trial Update: Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating SBC-103 for Mucopolysaccharidosis IIIB has completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Iiib

Drugs mentioned

• SBC-103 (recombinant human N-acetylglucosaminidase (NAGLU) enzyme)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Mucopolysaccharidosis IIIB | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-07-12